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Abstract 
Holocarboxylase synthetase (HCS) deficiency is an inherited disease of biotin metabolism characterized by a unique pattern of organic 
aciduria, metabolic acidosis, and skin lesions. By analysis of five patients in four unrelated families, two mutations were identified: a 
transition from T to C which causes an amino-acid substitution of proline for leucine at position 237 (L237P) and a single deletion of 
guanine (delG1067) followed by premature termination. One patient was homozygous for the L237P mutation, three patients in two 
families were compound heterozygotes of the missense and deletion alleles, and the other patient was heterozygous for the L237P 
mutation. Inheritance was successfully demonstrated in all of the patients’ families by a modified PCR followed by restriction enzyme 
digestion. The two mutations accounted for seven of eight mutant alleles, while neither mutation was detected in 108 normal healthy 
Japanese children (216 alleles). Transient expression in cultured fibroblasts from a patient showed that the L237P mutation was 
responsible for decreased HCS activity. These results suggest that the L237P and delG1067 mutations are frequent disease-causing 
mutations in Japanese patients with HCS deficiency. This PCR-based technique may therefore be useful for detecting mutations among 
Japanese patients. 
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1. Introduction 
Holocarboxylase synthetase (HCS) deficiency is an au- 
tosomal recessive disorder of organic acid metabolism in 
man [l]. HCS is an enzyme that catalyzes the binding of 
biotin to various carboxylases, using ATP for biotin activa- 
tion [2]. Most patients with this disease manifest such 
symptoms as tachypnea, feeding difficulties, seizures, and 
dermatitis in the early infantile period. The elevation of 
various organic acids in the urine indicates a defect in 
multiple carboxylases. The activities of various mitochon- 
drial carboxylases (pyruvate carboxylase, propionyl-CoA 
carboxylase and methylcrotonyl-CoA carboxylase) and cy- 
tosolic acetyl-CoA carboxylase have been reported to be 
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decreased in fibroblasts obtained from HCS-deficient pa- 
tients [3-51. The clinical symptoms are usually improved 
dramatically with the oral administration of 10 to 20 mg of 
biotin per day. HCS deficiency is a clinically heteroge- 
neous disorder. The age of onset varies from a few hours 
after birth to 15 months of age and the biotin dose required 
for controlling the clinical symptoms varies several fold 
[1,6]. The degree of decreased affinity of HCS for biotin 
has been demonstrated to correlate with the age of onset 
[6,71. 
We have recently purified HCS from bovine liver [8]. 
Using sequence data deduced by analysis of peptides from 
purified enzyme, we isolated human HCS cDNA clones 
[9]. The clones encode a polypeptide of 726 amino acids 
with a calculated molecular mass of 80759 Da. Isolation 
of HCS cDNA enabled us to identify a one base deletion 
(delGl067) that resulted in premature termination at amino 
acid 280 and a missense mutation (L237P) in cells from 
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siblings with HCS deficiency. However, it has not been 
determined whether the missense mutation accounts for the 
disease phenotype. 
The purpose of this study was to expand the analysis of 
HCS deficiency to new patients at the molecular level. 
Another goal was to develop a transient expression system 
of HCS and to determine whether the mutant protein was 
responsible for decreased HCS activity. 
2. Materials and methods 
2. I. Patients and cell lines 
Table 1 shows the clinical and biochemical data and 
outcome of five Japanese patients. Parents were not con- 
sanguineous in any family. Patient 1 developed metabolic 
ketoacidosis associated with severe neonatal distress within 
one day following birth. This patient responded to 10 mg 
per day of oral biotin which led to remarkable improve- 
ment of the clinical and biochemical abnormalities. Physi- 
cal and psychomotor development was normal on oral 
biotin (40 mg/day) at 9 months. However, her most recent 
intelligence quotient (IQ) score was only 66 at 5 years, 
although she has remained free of other symptoms. Patient 
2 manifested symptoms on the first day of life. High doses 
of biotin (80 mg/day) were required to control associated 
dermatitis. Patient 3 was discovered by detection of ele- 
vated leucine in a blood sample submitted for newborn 
mass screening. The patient was treated with IO mg of oral 
biotin per day and his IQ was 74 at 5 years of age. Patients 
4a and 4b have been described elsewhere [4,9]. 
Fibroblasts were maintained in minimum essential 
medium (MEM) supplemented with antibiotics and 10% 
FCS at 37°C in 5% CO,. Lymphoblastoid cell lines were 
Table I 
Clinical data of patients with HCS deficiency 
established by infection with Epstein-Barr virus and main- 
tained under the same conditions as fibroblasts except that 
RPM1 1640 was used instead of MEM. HCS activity in the 
cultured cells was determined by monitoring the rate of 
holoenzyme synthesis using apopropionyl-CoA carboxyl- 
ase from HCS-deficient cells as the substrate [8]. HCS 
activity in all the patients was less than 6% of the normal 
control value. 
2.2. Nucleotide sequence analysis of cDNA 
Total RNA was extracted from cultured lymphoblasts 
using a guanidinium thiocyanate/phenol/chloroform RNA 
extraction method [lo]. Poly(A’) RNA fractions were 
purified with an mRNA purification kit (Pharmacia 
Biotech, Uppsala, Sweden) and cDNA was synthesized as 
described previously [9]. The entire coding region of HCS 
cDNA was amplified by polymerase chain reaction (PCR) 
with four pairs of oligonucleotide primers in two overlap- 
ping fragments [9]. The DNA was subcloned into the 
XhoI-EcoRI site of pBluescript II KS + (Toyobo, Tokyo, 
Japan) and sequenced on an automated laser fluorescent 
(A.L.F.) sequencing apparatus (Pharmacia Biotech). 
2.3. Direct sequencing 
Genomic DNA was extracted from cultured lym- 
phoblastoid cells using the Sepa Gene kit (Sank0 Junyaku, 
Tokyo, Japan). One ,ug of genomic DNA was subjected to 
PCR amplification with primers S4 and AS5 (Table 2). 
Each amplification was performed in a volume of 30 ~1 
containing 200 pmol of each primer, IO mM Tris-HCl (pH 
8.81, 1.5 mM MgCl,, 50 mM KCI, 0.1% Triton X- 100, 
100 PM of each dNTP, and 2.5 units of Taq DNA 
polymerase (Wake, Osaka, Japan). Each of the 25 amplifi- 
Patient 1 2 3 4a 4b 
Sex 









Age at evaluation, years 
Intelligence quotient score 
%HCS activity of normal value 
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I 1 ? .I 
+ + - 
- + - 
- _ - 
- + - 
+ + - 
- + - 
+ + - 
5 7 5 
66 80 67 













UD ‘ 2 
Note: I + ’ = presence of symptom and ’ - ’ = absence of symptom. 
’ Found by detection of elevation of leucine in neonatal mass screening 
h Prenatal treatment. 
L Undetectable. 
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cation cycles consisted of denaturation at 94°C for 1 min, 
primer annealing at 55°C for 1 min, and extension at 72°C 
for 1 min. One ~1 of the first amplification was used as 
the template for the second PCR amplification. The sense 
primer had an Ml3 reverse sequence at the 5’ end (S- 
GGAAACAGCTATGACTTCTCTACCACCTGCTGGAG) 
and the antisense primer had a biotin group at the 5’ end 
(5’-biotin CTCAAGACGCTGAGCTTCACCTC). The 
thermoprofile of the second PCR was 30 cycles of 94’C 
for 1 mitt, 55°C for 1 min, and 72°C for 1 min. The PCR 
products were separated on a 1.5% low melting point 
agarose gel @MC , Rockland, ME) and DNA was recov- 
ered by using a Magic prep purification kit (Promega, 
Madison, WI). The purified DNA was immobilized onto 
Dynabeads M-280 streptavidin (Dynal, Oslo, Norway) and 
denatured in 0.1 M NaOH to single-stranded DNA. The 
single-stranded DNA was then sequenced on an A.L.F. 
sequencing apparatus using an Ml3 reverse primer as the 
sequencing primer to improve the quality of sequencing 
reactions. 
2.4. Construction of expression uectors 
The AgtlO DNA containing full-length HCS cDNA [9] 
was subjected to PCR in a IOO-~1 reaction mixture con- 
taining 20 pmol of each primer (S9 and AS9, Table 2), 20 
mM Tris-HCl (pH 8.2), 2 mM MgCl,, 10 mM KCl, 6 mM 
(NH4j2S04, 0.1% Triton X-100, 10 pg/ml BSA, 100 
PM of each dNTP, and 2.5 units of P’u DNA polymerase 
(Stratagene, La Jolla, CA). Each of the 30 amplification 
cycles consisted of denaturation at 94°C for 1 min, primer 
annealing at 60°C for 1 min, and extension at 74°C for 1 
min. The PCR product was digested with XhoI (Takara, 
Kyoto, Japan) and subcloned into the X/z01 site of pBlue- 
script II KS + . The nucleotide sequence was confirmed. 
The XhoI fragment containing the HCS coding sequence 
was isolated from the cloning vector and subcloned into 
Table 2 
Oligonucleotides used as PCR primers and AS0 hybridization probes 
the mammalian expression vector pCAGGS, described by 
Niwa et al. Ill]. To construct the mutant expression vector, 
the fragment between the BbsI (New England Biolabs, 
Beverly, MA) sites (positions 966 and 1025) was replaced 
with the cDNA with L237P. The upstream and down- 
stream ligation sites and the orientation of the cDNA were 
determined by sequencing. The vectors containing the 
normal and mutant (L237P) HCS cDNAs were designated 
as ‘pCAGGS-N’ and ‘pCAGGS-L237P’, respectively. 
2.5. Transient expression study 
HCS deficient fibroblasts from patient 4b were main- 
tained as described above. The transfection of fibroblasts 
was carried out by using Lipofectamine Reagent (Gibco 
BRL, Gaithersburg, MD) according to the manufacturer’s 
recommendations. Twenty pug of plasmid DNA was trans- 
fected with 80 ~1 of Lipofectamine Reagent per 150-mm 
dish. Five pg of pCAGGS-pgal, the vector containing 
Escherichia coli /3-galactosidase cDNA, was cotransfected 
as an internal standard. The transfected cells were har- 
vested by scraping 48 h after transfection, washed twice 
with PBS, and stored at - 80°C until use. 
Propionyl-CoA carboxylase (PCC) activity in the trans- 
fected fibroblasts was measured by a radioactive assay 
entailing the fixation of [I4 Clbicarbonate [12]. Lysate buffer 
(50 mM Tris-HCl (pH S.O>, 3 mM EDTA, and 2.5 mM 
reduced glutathione) was used instead of cell extracts as a 
blank assay. Protein concentration was determined by the 
method of Bradford [13]. P-galactosidase activity was 
measured by P-galactosidase enzyme assay kit (Promega). 
2.6. Modified PCR for the detection of L237P and 
delGl067 mutations 
Genomic DNA was extracted from either cultured fi- 
broblasts or lymphoblastoid cells as described above. Ex- 
PCR Primer ’ Location b Sequence 




























’ S = sense primer, AS = antisense primer. 
b Refers to the most 5’-nucleotide with respect to the ( + ) orientation. 
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tracting DNA from blood-blotted paper was carried out 
according to the method of Ogasawara et al. [14]. 
To facilitate the DNA analysis of the two mutations, we 
developed a method using restriction-site-generating PCR 
[ 151. A forward primer (S 10; S-TGTACCAGAAGTT- 
CATGGCGGATC) mismatches the HCS gene at the 20th 
and 2 1 st positions to create a BamHI site in PCR products 
amplified from the allele carrying the L237P mutation. To 
detect the delG1067 mutant alleles, the underlined nu- 
cleotides in the forward primer (S 11; 5’-GTGGCTTTCAG- 
GTGACAAGCCCGG) were changed from A to C to make 
a recognition sitefor SmaI in the PCR products amplified 
from the normal allele (Fig. 2). The first PCR was con- 
ducted with primers S4 and AS5 in the same condition as 
described before. One ~1 of the first amplification reaction 
was used as a template for the second PCR amplification 
using a pair of primers, SlO and AS5 or S 11 and AS5 
(Table 2). The thermoprofile of the second PCR was 30 
cycles of denaturation at 94°C for 1 min, annealing at 55°C 
for 1 min, and extension at 72°C for 1 min. The restriction 
enzyme digestion was performed in a total volume of 40 
,uI which contained 34 ~1 of PCR products, 20 U of SmaI 
or BumHI (New England Biolabs), and 4 ~1 of 10 X 
digestion buffers as supplied by the manufacturer. The 
electrophoresis was performed on a 6% agarose gel (2% 
SeaPlaque (FMC) plus 4% Agarose S (Nippongene, 
Toyama, Japan)). The DNA fragments were stained with 
0.5 pug/ml of ethidium bromide. 
2.7. Allele-spec$c oligonucleotide (ASO) hybridization 
The DNA fragment containing both the L237P and 
delG1067 sites was amplified with 1 pg of genomic DNA 
by semi-nested PCR with primers S4 and AS5 followed by 
primers S8 and AS5 (Table 2). The PCR products (189 bp 
length) were subjected to electrophoresis on an agarose gel 
(4 X 11 cm) and transferred onto a Gene screen plus nylon 
membrane (New England Nuclear, Boston, MA) by an 
alkaline transfer method [16]. The AS0 detection probes 
are shown in Table 2. The probes were radiolabeled with 
T4 polynucleotide kinase (Toyobo) and [ y- 32 P]ATP 
(Amersham, Buckinghamshire, UK). The filter was finally 
washed in 2 X SSC/O. 1% SDS at 37°C for 10 min. 
3. Results 
3. I. tdentificution of the mutation in patient I 
During the course of sequencing cDNA from patient 1, 
a T to C substitution at nucleotide position 997 (L237P) 
was found in all five clones isolated. To determine if the 
patient was homozygous for alleles containing the L237P 
mutation, the genomic DNA fragment containing the muta- 
tion was amplified and directly sequenced using the solid 
237 




Fig. I. Direct sequencing of genomic DNA from patient I. The arrow 
indicates a T to C substitution at nucleotide position 997, suggesting 
homozygosity for this mutation. 
phase method. Fig. 1 shows that patient 1 is a homozygote 
for the L237P mutation. 
3.2. Transient expression study 
To determine whether this substitution was responsible 
for decreased HCS activity, we made wild and mutant 
(L237P) expression constructs. Vectors containing normal 
and mutant (L237P) cDNA were transfected into HCS 
deficient fibroblasts obtained from patient 4b. PCC activity 
in the transformants 48 h after transfection with the wild- 
type cDNA (pCAGGS-N) was 12.1 -t 1 .O (mean * SD., 
n = 41, which was about 3-fold higher than that of the 
intrinsic activity (4.2 f 0.6; mean + S.D., n = 2) (Table 
3). In contrast, no significant increase in PCC activity was 
observed in fibroblasts transfected with the pCAGGS- 
Table 3 
Analysis of PCC and fl-galactosidase activities in HCS-deficient fibrob- 
lasts transfected with either normal or mutant HCS cDNA 
Propionyl-CoA P-Galactosidase 
carboxylase a (mU/mg) 
(pmol/min per mg) 
HCS (- ) fibroblasts (n = 2) 4.2 f 0.6 
with pCAGGS-N (n = 4) 12.1* I.0 h 2.4*0.3 
with pCAGGSL237P (n = 4) 4.7 + I .4 2.2 + 0.2 
’ Activity was assayed in duplicate for each dish. 
b A significant difference between HCS-deficient cells and pCAGGS-N 
transfected cells. P < 0.001, as determined by t-test). 
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Fig. 2. Schematic illustration of a PCR-generating restriction enzyme method for detecting the (A) L237P and (B) delG1067 mutations. The asterisks 
indicate mismatched residues generating restriction sites. In regard to the L237P mutation, the PCR products amplified from the mutant allele can be 
digested by BamHI (A). The products from the normal allele can be digested with SmaI and the products carrying the delGl067 allele retain the original 
size (Bl. Lane W, normal allele. Lane M, mutant allele. 
L237P (4.7 & 1.4; mean + S.D., II = 4). Western blot anal- 
ysis of transfected fibroblasts revealed that the size and 
amount of the mutant enzyme expressed in the cells were 
similar to those of the wild-type enzyme (data not shown). 
There was no significant difference in P-galactosidase 
activity between dishes. These results suggest that while 
the isolated cDNA clone boosted HCS activity in eukary- 






Fig. 3. (Al Detection of mutations in family members of patients with HCS deficiency by restriction-site generating PCR. Modified PCR was performed 
followed by either BamHI or SmaI digestion. The digested DNA fragments were separated on a 6% agarose gel and stained by ethidium bromide. The 
patients are numbered as indicated in Table 1. Carriers are shown by half-blackened boxes (L237P) and half boxes with an oblique line (delGlO671. The 
L237P mutation was found in patients 2, 3, 4a, and 4b in the heterozygous form and in patient 1 in the homozygous form. The single guanine base deletion 
was found in patients 2, 4a, and 4b in the heterozygous form. Lane C, normal control. (B) Allele-specific oligonucleotide (AS01 hybridization for detecting 
the L237P mutation and the delGl067 mutation in Japanese patients. The results were compatible with those of the PCR-restriction enzyme method. 
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3.3. Analysis of genotype in j&e patients and their family origins for a more complete understanding of the range of 
members HCS mutant genotypes. 
Genomic DNAs were extracted from dried blood spots 
from patient 3 and family members of the five patients or 
from cultured lymphoblasts of patients 1, 2, 4a, and 4b. 
When the DNA which contained the L237P mutation was 
amplified by PCR with primers SlO and AS5, digestion 
with BamHI produced fragments of 152 bp and 20 bp 
(Fig. 2). The PCR product with the normal allele retained 
the original size after digestion. For detecting the delG 1067 
mutant allele, PCR with primers Sl 1 and AS5 followed by 
SmaI digestion was carried out. The PCR products contain- 
ing the normal sequence were digested into 75 bp and 25 
bp products, while those containing the mutant were not. 
The following observations suggest that the L237P 
mutation was causative for HCS deficiency. First, intro- 
duction of an expression vector containing mutant cDNA 
failed to increase PCC activity in transfected cells. Second, 
the mutation was not detected in 108 healthy Japanese 
children, being segregated exclusively among patients with 
HCS deficiency. The substitution of proline for leucine has 
been reported in various hemoglobinopathies [ 17,181, CK- 
thalassemia [19], and Gaucher’s disease [20]. This substitu- 
tion has been shown to destabilize the protein secondary 
structure in these diseases [ 17,181. 
The L237P mutation was identified in patients 2, 3, 4a, 
and 4b in the heterozygous form and in patient 1 in the 
homozygous form (Fig. 3A, the 20bp bands are not shown 
in this figure). The single guanine deletion was found in 
patients 2, 4a, and 4b in the heterozygous form. Of the 
eight alleles analyzed, the L237P mutation occurred in five 
alleles and the delG1067 in two. Another mutation was not 
identified in cDNA of patient 3. The same approach was 
applied to the detection of two mutations in family mem- 
bers of the patients. The two mutations showed a Mendelian 
inheritance pattern in all families without exception. The 
results obtained by this method were confirmed by AS0 
hybridization analysis (Fig. 3B). The L237P and delG1067 
mutations were screened by AS0 analysis in DNAs from 
blood spots from 108 normal healthy Japanese children 
(2 16 alleles, data not shown). No alleles contained the two 
mutations. 
High doses of biotin (20-60 mg/day) were required to 
control clinical symptoms in patients 2, 4a, and 4b. Inter- 
mittent respiratory infections have led to metabolic acido- 
sis or organic aciduria in spite of biotin therapy in patients 
4a and 4b. In contrast, patients 1 and 3 responded to 10 to 
20 mg biotin per day and abnormal urinary metabolites 
virtually disappeared. Homology to BirA, which has DNA 
binding and HCS activity in E. coli [21,22], has suggested 
that the ATP and biotin binding sites are located in the 
3’-region downstream from amino acid 500 of the HCS 
protein [9]. Since the single base deletion of G at nu- 
cleotide position 1067 results in premature termination at 
position 280, the truncated polypeptide would lack the 
biotin and ATP binding domains, which are essential for 
HCS activity. It is very likely that this mutant polypeptide 
shows no enzymatic activity. The current evidence sug- 
gests that the allele containing one base deletion is related 
to the more severe symptoms in patients 2, 4a, and 4b. 
4. Discussion 
It is likely that the L237P and delG1067 mutations are 
predominant among Japanese patients, although the num- 
ber of alleles studied is too small for a definitive conclu- 
sion. Among the five patients in the four unrelated families 
analyzed, one patient was homozygous for L237P, three 
patients in two families were compound heterozygotes of 
the missense and deletion alleles, and the other patient was 
heterozygous for the L237P mutation. Thus these two 
mutations accounted for seven of eight mutant alleles in 
these unrelated families, while neither mutation was de- 
tected in 216 alleles from normal healthy children. It is 
unknown why these mutations are prevalent in Japan. The 
L237P mutation does not occur at a CpG dinucleotide, 
which tends to be a hot spot for mutation. It is conceivable 
that these patients share a common ancestor although the 
four families reside in various regions of Japan and are not 
consanguineous as far as we know. The lack of polymor- 
phic markers at or near the HCS locus precludes genetic 
analysis of relatedness. It would be of interest to determine 
the nature of mutations in patients from other ethnic 
In the transient expression study, the level of PCC 
activity increased significantly in fibroblasts transfected 
with wild-type HCS cDNA. This observation strongly 
suggested that the expressed HCS catalyzed biotinylation 
of apo-PCC in HCS-deficient fibroblasts. HCS activity is 
found in both mitochondria and cytosol in chicken [23] and 
mammalian cells [8,24,25]. Little is known about the na- 
ture of the two enzymes and it is unknown where and by 
which type of HCS mitochondrial carboxylases are bio- 
tinylated. There are two possible hypotheses to explain 
where expressed HCS protein catalyzes the incorporation 
of biotin into apo-PCC. First, the protein expressed from 
HCS cDNA is translocated into mitochondria and cat- 
alyzes the incorporation of biotin into existing or newly 
translocated apo-PCC. Second, the HCS remains in the 
cytosol and incorporates biotin into the newly synthesized 
PCC precursor. The biotinylated PCC precursor is then 
transported into the mitochondria. Although we have no 
direct experimental evidence, we believe that the isolated 
cDNA encodes a cytosolic protein because no authentic 
mitochondrial leader sequence exists at the NH, terminus 
[9]. It has been reported that the a-subunit precursor of 
PCC accumulates in the cytoplasm and is biotinylated 
before translocation occurs [26]. We speculate that PCC is 
biotinylated by the expressed cytosolic HCS, translocated 
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into the mitochondria and then processed to the active 
protein. Analysis of the intracellular localization of ex- 
pressed HCS is necessary to confirm this hypothesis. 
Early diagnosis of HCS deficiency is crucial, because 
administration of biotin can prevent the occurrence of 
life-threatening ketoacidosis. Assays for either multiple 
carboxylases or HCS have been the only means available 
to establish the diagnosis of HCS deficiency. DNA analy- 
sis will provide another tool for diagnosing the disease. 
We developed a PCR-restriction enzyme method to detect 
two frequent mutations accurately and rapidly. Dried blood 
spots on filter paper, which may be stored and transported 
easily, were utilized as the source of DNA for this method. 
Although DNA analysis is not always informative, this 
method should facilitate, at least in Japan, definitive and 
rapid prenatal/postnatal diagnosis in families with HCS 
deficiency. 
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